FindTrial
Sign In

CLINICAL SAFETY EVALUATION OF MERCURY BASED SIDDHA MEDICINE(RASAGANDHI MEZHUGU)

CLINICAL SAFETY EVALUATION OF MERCURY BASED SIDDHA MEDICINE(RASAGANDHI MEZHUGU) IN NIS OPD AND IPD PATIENTS

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019060
Enrollment
50
Registered
2019-05-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L303- Infective dermatitis

Interventions

Intervention1: Drug Name-Capsule.Rasagandhi mezhugu.: Drug Name-Capsule.Rasagandhi mezhugu. Dose - 2 capsules Twice A day. Duration-48 days. Rasagandhi mezhugu is a one of the siddha medicine it will

Sponsors

NATIONAL INSTITUTE OF SIDDHA CHENNAI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PATIENTS WHO TAKING RASAGANDHI MEZHUGU FOR 48 DAYS

Exclusion criteria

Exclusion criteria: PATIENTS WITH THE HISTORY OF ANY MAJOR SYSTEMIC ILLNESS AT THE START OF THE TREATMENT

Design outcomes

Primary

MeasureTime frame
1.TO PROVE THAT TAKING RASAGANDHI MEZHUGU FOR 48 DAYS TO CREATE ANY CHANGES IN BLOOD PARAMETERS. 2.TO ANALYSE THE PRESENCE OF MERCURY LEVEL IN BLOOD THROUGH ICP-MS METHODTimepoint: 1.TO PROVE THAT TAKING RASAGANDHI MEZHUGU FOR 48 DAYS TO CREATE ANY CHANGES IN BLOOD PARAMETERS. 2.TO ANALYSE THE PRESENCE OF MERCURY LEVEL IN BLOOD THROUGH ICP-MS METHOD—

Secondary

MeasureTime frame
TO PROVE THAT TAKING RASAGANDHI MEZHUGU FOR 48 DAYS TO CREATE ANY CHANGES IN BLOOD PARAMETERS. 2.TO ANALYSE THE PRESENCE OF MERCURY LEVEL IN BLOOD THROUGH ICP-MS METHODTimepoint: TO PROVE THAT TAKING RASAGANDHI MEZHUGU FOR 48 DAYS TO CREATE ANY CHANGES IN BLOOD PARAMETERS. 2.TO ANALYSE THE PRESENCE OF MERCURY LEVEL IN BLOOD THROUGH ICP-MS METHOD—

Countries

India

Contacts

Public ContactDR B PRATHISHA

NATIONAL INSTITUTE OF SIDDHA

Sppriyaathamu@gmail.com9962513101

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026